| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2003-07-2462 |
| P8608 | Fatcat ID | release_zusae5ttsrcefba5cft6yvsaou |
| P698 | PubMed publication ID | 14576047 |
| P5875 | ResearchGate publication ID | 9040453 |
| P50 | author | Javier de la Serna | Q57015481 |
| P2093 | author name string | Dolors Colomer | |
| Marcos González | |||
| Miguel A Sanz | |||
| Eva Barragán | |||
| María J Calasanz | |||
| Gustavo A Milone | |||
| Guillermo Martín | |||
| Silvia Negri | |||
| Chelo Rayón | |||
| Concha Rivas | |||
| Juan Bergua | |||
| Pascual Bolufer | |||
| Angel León | |||
| Ricardo Parody | |||
| Lourdes Escoda | |||
| Francisco J Capote | |||
| Elena Amutio | |||
| José Román | |||
| Javier De La Serna | |||
| Programa de Estudio y Traitmiento de las Hemopatías Malignas | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute promyelocytic leukemia | Q612108 |
| tretinoin | Q29417 | ||
| leukemia | Q29496 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 1237-1243 | |
| P577 | publication date | 2003-10-23 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group | |
| P478 | volume | 103 |
| Q41742084 | A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia |
| Q39103005 | ATRA and anthracycline-based chemotherapy in the treatment of childhood acute promyelocytic leukemia (APL): A 10-year experience in Tunisia |
| Q35955272 | Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia |
| Q92226418 | Acute Promyelocytic Leukemia and HIV: Case Reports and a Review of the Literature |
| Q36125618 | Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF). |
| Q37617605 | Acute promyelocytic leukemia in childhood |
| Q35640734 | Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era |
| Q38132719 | Acute promyelocytic leukemia: do we have a new front-line standard of treatment? |
| Q37693929 | Acute promyelocytic leukemia: what are the treatment options? |
| Q26830385 | Acute promyelocytic leukemia: where did we start, where are we now, and the future |
| Q35904994 | Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia |
| Q33707423 | Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. |
| Q36429723 | Advances in the treatment for haematological malignancies |
| Q37905921 | Advances in therapies for acute promyelocytic leukemia |
| Q37782114 | Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia |
| Q36497421 | Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia |
| Q38055497 | All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. |
| Q34054167 | Arsenic trioxide - An old drug rediscovered |
| Q58763229 | Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial |
| Q33781722 | Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy |
| Q24239914 | Arsenic trioxide for the treatment of acute promyelocytic leukaemia |
| Q94325709 | Arsenic trioxide for the treatment of acute promyelocytic leukaemia |
| Q34310859 | Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. |
| Q38815519 | Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. |
| Q36255287 | Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia |
| Q64889737 | Availability of all-trans retinoic acid and support systems for management of acute promyelocytic leukemia in Michigan and Louisiana, USA. |
| Q33377454 | Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? |
| Q39638942 | C/EBPβ and CHOP participate in Tanshinone IIA-induced differentiation and apoptosis of acute promyelocytic leukemia cells in vitro |
| Q44846741 | CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia. |
| Q88913331 | Cell dynamics during differentiation therapy with all-trans retinoic acid in acute promyelocytic leukemia |
| Q37334952 | Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. |
| Q33625750 | Central nervous system involvement of acute promyelocytic leukemia, three case reports. |
| Q54614959 | Central nervous system relapse in CD56+, FLT3/ITD+ promyelocytic leukemia. |
| Q43104414 | Central nervous system relapse in a patient with acute promyelocytic leukaemia: does the risk stratification matter? |
| Q38891536 | Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide |
| Q34953881 | Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre |
| Q35640760 | Clinical features and treatment outcome of acute promyelocytic leukemia patients treated at cairo national cancer institute in egypt |
| Q36410195 | Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations |
| Q38798789 | Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis |
| Q38197074 | Contemporary treatment of APL |
| Q51474049 | Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. |
| Q37267500 | Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States |
| Q33613426 | Curing all patients with acute promyelocytic leukemia: are we there yet? |
| Q92158117 | Current first- and second-line treatment options in acute promyelocytic leukemia |
| Q38674575 | Current standard treatment of adult acute promyelocytic leukaemia |
| Q36539598 | Current therapeutic strategies for acute myeloid leukaemia |
| Q33279222 | Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents |
| Q46374987 | Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. |
| Q36913223 | Diagnosis and treatment of acute promyelocytic leukemia. |
| Q37848580 | Differentiation syndrome in patients with acute promyelocytic leukemia |
| Q42720957 | Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia |
| Q34541742 | Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group |
| Q34480479 | Early Detection of t(8;21) Chromosomal Translocations During Treatment of PML-RARA Positive Acute Promyelocytic Leukemia: A Case Study |
| Q36938551 | Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin |
| Q36612619 | Emerging new approaches for the treatment of acute promyelocytic leukemia |
| Q46819268 | Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. |
| Q42078133 | FISH detection of PML-RARA fusion in ins(15;17) acute promyelocytic leukaemia depends on probe size |
| Q80538904 | Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood |
| Q48346019 | Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines |
| Q36630107 | Guidelines on the management of acute myeloid leukaemia in adults |
| Q64119389 | Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia |
| Q51764847 | Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. |
| Q42328350 | High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study |
| Q43294483 | High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA. |
| Q34091115 | High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure |
| Q46448331 | High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia |
| Q43488302 | Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology |
| Q37994088 | How to manage acute promyelocytic leukemia |
| Q88315468 | Hypercalcemia and acute pancreatitis in a male patient with acute promyelocytic leukemia and pulmonary tuberculosis |
| Q46515800 | Hypercalcemia due to an interaction of all-trans retinoic acid (ATRA) and itraconazole therapy for acute promyelocytic leukemia successfully treated with zoledronic acid |
| Q55004742 | Hyperfibrinolysis Is an Important Cause of Early Hemorrhage in Patients with Acute Promyelocytic Leukemia. |
| Q55412183 | Incident adverse events following therapy for acute promyelocytic leukemia. |
| Q57224260 | Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL) |
| Q54373374 | Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. |
| Q39494709 | Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells |
| Q37687421 | Integrating microRNA and mRNA expression profiles of acute promyelocytic leukemia cells to explore the occurrence mechanisms of differentiation syndrome |
| Q44693583 | International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia |
| Q54262480 | Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. |
| Q37738444 | Is cytarabine required in the treatment of acute promyelocytic leukemia? |
| Q33829079 | Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients |
| Q42714159 | Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia |
| Q47734635 | Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia |
| Q86483914 | Long-term follow-up of homoharringtonine plus all-trans retinoic acid-based induction and consolidation therapy in newly diagnosed acute promyelocytic leukemia |
| Q40413191 | Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab |
| Q53486790 | Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. |
| Q44242245 | Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients |
| Q37718455 | Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia |
| Q38108471 | Management of elderly patients with acute promyelocytic leukemia: progress and problems |
| Q88619377 | Management of patients with acute promyelocytic leukemia |
| Q37908158 | Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible? |
| Q41016121 | Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia. |
| Q59133781 | Melatonin Can Strengthen the Effect of Retinoic Acid in HL-60 Cells |
| Q42756928 | Melatonin promotes puromycin-induced apoptosis with activation of caspase-3 and 5'-adenosine monophosphate-activated kinase-alpha in human leukemia HL-60 cells |
| Q53173147 | Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia. |
| Q36816685 | Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia |
| Q37683361 | Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study |
| Q50519900 | Optimising absorption of posaconazole. |
| Q45163579 | Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. |
| Q36508333 | Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group |
| Q89791811 | Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study |
| Q62078702 | Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention |
| Q37973346 | Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. |
| Q27012691 | Pathophysiology, clinical features and radiological findings of differentiation syndrome/all-trans-retinoic acid syndrome |
| Q46981618 | Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor |
| Q34750640 | Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis |
| Q53090417 | Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study. |
| Q35265901 | Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy |
| Q38221006 | Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction |
| Q92647724 | Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia |
| Q84797439 | Prospective study of a therapeutic regimen with all‐trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study |
| Q35537150 | Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy |
| Q42576165 | Real-time consensus on relapse risk in acute promyelocytic leukemia |
| Q38025789 | Recent advances in the understanding and treatment of pediatric leukemias |
| Q46158349 | Recurrent differentiation syndrome or septic shock? Unresolved dilemma in a patient with acute promyelocytic leukemia |
| Q36494308 | Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials |
| Q35717816 | Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia |
| Q37712353 | Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives |
| Q37614062 | Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. |
| Q37785493 | Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review |
| Q34226368 | SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. |
| Q54592312 | Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. |
| Q33800102 | Single-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia |
| Q43357300 | Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. |
| Q37429222 | Survival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol |
| Q37397791 | Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. |
| Q36108610 | Targeted therapy for hematologic malignancies |
| Q82263678 | The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience |
| Q37952402 | The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia |
| Q24200224 | The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission |
| Q36103497 | Therapeutic research in untreated acute promyelocytic leukemia |
| Q42175003 | Therapeutic targeting of cancer stem cells |
| Q35540812 | Treatment of Acute Promyelocytic Leukemia with AIDA Based Regimen. Update of a Tunisian Single Center Study |
| Q50323734 | Treatment of Acute Promyelocytic Leukemia with Single Agent Arsenic Trioxide: Experience from a Tertiary Care Center in India |
| Q37498872 | Treatment of acute promyelocytic leukemia during pregnancy |
| Q39103020 | Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience |
| Q27851636 | Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients |
| Q36220730 | Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia |
| Q92438473 | Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia |
| Q41894404 | Update on optimal management of acute myeloid leukemia |
| Q40941767 | Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia |
| Q46043151 | Use of tranexamic acid for disseminated intravascular coagulation with excessive fibrinolysis associated with aortic dissection in a patient with chronic renal failure |
| Q35553795 | Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia |
| Q38204310 | What is the standard regimen for patients with acute promyelocytic leukemia? |
| Q89257239 | [Clinical features and prognostic analysis of high-risk acute promyelocytic leukemia patients] |
| Q53483035 | [The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients]. |
| Q27853031 | Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Le |
Search more.